Abstract Number: VPB0791
Meeting: ISTH 2022 Congress
Theme: Platelet Disorders, von Willebrand Disease and Thrombotic Microangiopathies » Antiplatelet Therapy
Background: The recovery rate of platelet COX-1 activity during the 12 to 24h dosing interval of aspirin administration, in aspirin-treated subjects, is characterized by substantial interindividual variability. Circulating myeloid-related protein (MRP)-8/14 is an inflammatory protein associated with residual thromboxane (TX)-dependent platelet activation in aspirin-treated patients with acute coronary syndrome.
Aims: To identify any circulating miRNAs associated with a suboptimal ASA response in patients at high cardiovascular (CV) risk.
Methods: Two-hundred high CV risk patients (100 with type 2 diabetes mellitus (T2DM)) in chronic treatment with ASA (100 mg/day), for cardiovascular prevention, were enrolled. Blood sampling was performed at 10 (T10) and 24 hours (T24) after a witnessed ASA administration. Patients were stratified in tertiles according to serum TXB2 slope. First vs. third tertile were compared. Circulating miRNAs custom array cards were applied to assay the expression levels of 14 miRNAs in plasma. We also measured plasma myeloid-related protein (MRP)-8/14 as an inflammatory index and predictor of cardiovascular events.
Results: miRNA-21-5p (p=.017), 22-5p (p=.026), 24-3p (p=.020), 150-5p (p=.026), 155-5p (p=.007), 181b-5p (p=.011), 223-5p (p=.021) were significantly lower in first vs. third tertiles at 24 hours after ASA administration in all patients (FIG.1). MRP-8/14 were higher in third vs. first sTXB2 slope tertile in all patients. MRP-8/14 was directly correlated with miRNA-21-5p (rho=.279, p=.008), 22-5p (rho=.264, p=.012), 24-3p (rho=.239, p=.023), 150-5p (rho=.236, p=.025), 155-5p (rho=.270, p=.011), 181b-5p (rho=.240, p=.023) and 223-5p (rho=.244, p=.030) in all patients.
Conclusion(s): MRP 8/14 may contribute to circulating miRNA release and response variability to ASA. Vice versa, shorter duration of aspirin effect at 24 hours in third sTXB2 slope tertile patients translates into higher degree of TX-dependent platelet activation, possibly promoting the release of both circulating MRP8/14 and miRNAs.
Reduced levels of circulating miRNAs may be a potential biomarker for predicting response to ASA treatment in high-risk cardiovascular patients.
Analysis of extracellular circulating miRNAs
To cite this abstract in AMA style:
Liani R, Simeone P, Ciotti S, Tripaldi R, Boccatonda A, D'Ardes D, Recchiuti A, Romano M, Cipollone f, Santilli F. Circulating miRNAs release predicts suboptimal response to aspirin in patients at high cardiovascular risk with and without type 2 diabetes mellitus [abstract]. https://abstracts.isth.org/abstract/circulating-mirnas-release-predicts-suboptimal-response-to-aspirin-in-patients-at-high-cardiovascular-risk-with-and-without-type-2-diabetes-mellitus/. Accessed March 22, 2024.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/circulating-mirnas-release-predicts-suboptimal-response-to-aspirin-in-patients-at-high-cardiovascular-risk-with-and-without-type-2-diabetes-mellitus/